What one share of Decoy Therapeutics holds
We are a pre-clinical stage biotechnology company focused on advancing our pipeline of peptide conjugate therapeutics engineered through our proprietary IMP3ACT™ platform.
Decoy Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$40.66 |
|---|---|
| Cash and investments | $15.58 |
| Book value | $8.12 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$69.54 | $0.00 | −$56.44 | — | — |
| 2025 | — | −$129.10 | $5.95 | −$55.73 | — | $11.07 |
Common questions about Decoy Therapeutics
How much does one share of Decoy Therapeutics earn?
Over the last 12 months, Decoy Therapeutics lost $40.66 for each share.
Does Decoy Therapeutics pay a dividend?
Decoy Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Decoy Therapeutics’s book value per share?
Decoy Therapeutics’s book value is $8.12 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Decoy Therapeutics have?
Each share of Decoy Therapeutics has $15.58 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.